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Abstract 
 
Two long and one truncated isoforms (termed LAP*, LAP, and LIP, respectively) of the 
transcription factor C/EBPβ are expressed from a single intronless Cebpb gene by 
alternative translation initiation. Isoform expression is sensitive to mTOR mediated activation 
of the translation initiation machinery and relayed through an uORF on the C/EBPβ mRNA. 
The truncated C/EBPβ LIP, initiated by high mTOR activity, has been implied in neoplasia, 
but it was never shown whether endogenous C/EBPβ LIP may function as an oncogene. In 
this study we examined spontaneous tumor formation in C/EBPβ knockin mice that 
constitutively express only the C/EBPβ LIP isoform from its own locus. Our data show that 
deregulated C/EBPβ LIP predisposes to oncogenesis in many tissues. Gene expression 
profiling suggests that C/EBPβ LIP supports a pro-tumorigenic microenvironment, resistance 
to apoptosis, and alteration of cytokine/chemokine expression. The results imply that 
enhanced translation re-initiation of C/EBPβ LIP promotes tumorigenesis. Accordingly, 
pharmacological restriction of mTOR function might be a therapeutic option in tumorigenesis 
that involves enhanced expression of the truncated C/EBPβ LIP isoform. 
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Introduction 
 
The C/EBPβ transcription factor belongs to the basic leucine zipper (bZip) CCAAT enhancer 
binding protein (C/EBP) family and controls cell fate in many tissues. C/EBPβ is involved in 
cell growth, proliferation, differentiation, apoptosis, senescence, and tumor tolerance. Cebpb 
is a single exon gene, yet three isoform proteins of variable N-terminal length are expressed 
from internal AUG start sites. The two long isoforms (C/EBPβ LAP* and LAP) are both 
transcriptional activators, but differ by 21 N-terminal amino acid residues that entail 
chromatin regulatory capacity. The truncated C/EBPβ LIP isoform lacks the N-terminal 185 
amino acid residues, removing the entire transactivation domain and part of the regulatory 
domain. C/EBPβ LIP is thought to dominantly counteract tumor suppressive functions of 
other C/EBP family members, suggesting C/EBPβ LIP as a potential oncogene [1, 2].  
 
A highly conserved (from fish to man) small upstream open reading frame (uORF) in the 5’ 
mRNA region regulates alternative translation initiation of Cebpb at consecutive in frame 
start sites. Previous data showed that translation of the uORF restrains initiation of C/EBPβ 
LAP and causes resumption of ribosomal scanning and reinitiation at the downstream 
C/EBPβ LIP start site. The translational control and C/EBPβ isoform switching depends on 
mTOR signaling [3-6], stress response pathways [7], and RNA binding-proteins [8]. Briefly, 
at high activity of the translation initiation machinery the C/EBPβ LIP isoform is preferentially 
produced, whereas at low activity the long C/EBPβ LAP isoform is preferentially produced [9, 
10]. Recent evidences suggested that the C/EBPβ LAP:LIP ratio is an important indicator of 
C/EBPβ functions. Regulation of C/EBPβ LAP:LIP ratio plays a key role in liver regeneration, 
acute phase response, bone homeostasis, and mammary gland development [9, 10]. 
Enhanced expression of C/EBPβ was observed in human tumors, including mammary 
carcinomas [11-13], anaplastic large cell lymphoma (ALCL) [14-16], endometrial 
adenocarcinoma [17], ovarian [18], colorectal [19], liver [7] and skin cancer [20]. Among 
these, enhanced expression of the truncated C/EBPβ LIP isoform was reported in breast, 
ALCL, ovarian and colorectal neoplasia. C/EBPβ LIP also supports metastasis survival in 
breast cancer [21] and pharmacological inhibition of C/EBPβ LIP expression reduced ALCL 
proliferation, implying a causal relationship between C/EBPβ LIP isoform expression and 
tumorigenesis [14].  
 
Here, we used recombinant mouse genetics to explore whether deregulated expression of 
C/EBPβ LIP from its own genomic locus supports spontaneous tumor formation. A knockin 
mouse strain that expresses the C/EBPβ LIP isoform (LIP ki) developed tumors in multiple 
 
 
 4 
tissues of mesenchymal and epithelial origin, providing experimental evidence that 
enhanced translation re-initiation of C/EBPβ LIP is involved in tumorigenesis. 
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Materials and Methods 
 
Animals 
The generation of C/EBPβ knockout (ko) and LIP ki mice have been previously described [9, 
22]. The C/EBPβ ko and LIP ki mice were maintained on a 129 X C57BL/6 genetic 
background. Mice were fed with standard mouse diet and water ad libitium on a 12-h light-
dark cycle. Animals were housed in a pathogen free facility at the Max-Delbrück-Center for 
Molecular Medicine, Berlin. All procedures and animals experiments were conducted in 
compliance with protocols approved by the institutional Animal Care and Use Committee. 
Mice were sacrificed by cervical dislocation. All efforts were made to minimize animal 
suffering. 
 
Histopathological analyses 
Mice were sacrificed upon substantial decline in health (i.e. weight loss, paralysis, ruffling of 
fur or inactivity) or obvious tumor burden. Tissues were fixed in buffered 4% formaldehyde at 
4°C, dehydrated and paraffin embedded. Sections (4µm) were stained with hematoxylin and 
eosin according to standard procedures. To perform immunohistochemical (IHC) staining 
slides were immersed in sodium citrate buffer solutions at pH 6.0, heated in a high-pressure 
cooker for 5 min, rinsed in cold water and washed in Tris-buffered saline (pH 7.4), and were 
then treated with a peroxidase-blocking reagent (Dako) before incubation for 1 h with the 
primary antibody for B220 (RA3-6B2, eBioscience) or cleaved-caspase 3 (Asp175, Cell 
Signaling). Binding was detected by the Envision peroxidase kit (K4010, Dako) using 
diaminobenzidine as chromogenic substrate. Sections were analyzed using an AxioPlan-2 
microscope (Zeiss, Germany). Images were acquired using a Zeiss AxioCam Hr camera and 
AxioVision software version 4.2. For cleaved-caspase 3 IHC analysis, per animal five 
randomly chosen microscope fields were captured at 200 x magnification. The number of 
cleaved-caspase 3 positive cells/field were counted and expressed as fold of control. 
 
Cell culture and immunoblotting 
Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos and spontaneously 
immortalized according to standard protocols. 3T3-L1 murine preadipocytes (ATCC, 
American Type Culture Collection) and MEFs were cultured in DMEM (Invitrogen) 
supplemented with 10% FBS (Invitrogen). Tissues, lymphoma and cells were lysed with 8 M 
urea lysis buffer. Proteins were separated by SDS/PAGE followed by Western blot analysis 
using rabbit C/EBPβ antibody (C19, Santa Cruz) and mouse anti-α-tubulin (B-7, Santa Cruz) 
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or mouse anti-β-tubulin (2-28-33, Sigma). Appropriate horseradish peroxidase-conjugated 
secondary antibodies were used for chemiluminescence (Amersham Biosciences). 
 
RNA preparation and Microarray gene expression profiling 
Total RNA from 5 +/L and 5 WT lymphoma was prepared using the TriPure Isolation 
Reagent (Roche) and analyzed on a 4x44K whole genome mouse microarray (Agilent 
Technologies). For normalization, quality control, and data analysis, the Bioconductor 
system was used (http://www.bioconductor.org) [23]. Raw microarray data from Agilent were 
first quantile normalized. For identification of differentially expressed genes, a linear model 
was fitted using limma. The fold change cutoff was set to 2 (FC = 2) and the P value cutoff 
was selected as 0.05. For functional analysis, GSEA was performed using GSEA v2.0 
algorithm (http://www.broadinstitute.org/gsea) [24] and the computed t-statistic from limma 
as pre-ranking. The following gene sets from MSigDB database 
(http://www.broadinstitute.org/gsea) were used: C2: curated sets, canonical pathways, 
Biocarta, KEGG, Reactome and C5: Go gene sets, BP: biological process. Only gene sets 
showing nominal P value ≤ 0.05 and false discovery rate (FDR) ≤ 0.25 were taken into 
consideration.  
 
Statistical analysis 
All data are expressed as mean ± s.e.m. Statistically significant differences between groups 
were determined using the unpaired two-tailed Mann-Whitney’s test for the histographs and 
the Log-rank test for the Kaplan-Meier curves. Both tests were performed using Prism 5 
(GraphPad Software). A P value <0.05 was considered to be statistically significant. 
 
Accession number 
The raw microarray data were deposited at Gene Expression Omnibus (GEO accession 
number: GSE53770)  
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Results 
 
LIP ki mice are cancer prone 
 
An excess of C/EBPβ LIP has been suggested to promote metastatic breast cancer by 
interfering with the TGFβ cytostatic pathway and/or by inhibition of anoikis [21, 25]. 
Moreover, expression of Cebpb LIP as a transgene under the whey acidic promoter led to 
mammary gland hyperplasia and rare neoplasia [26]. Although these experimental 
approaches have hinted at an oncogenic potential of C/EBPβ LIP, they did not reflect 
organismal constraints in quantitative, spatial and temporal Cebpb regulation from its own 
locus. 
 
To examine whether enhanced endogenous C/EBPβ LIP expression is involved in 
tumorigenesis, cohorts of 45 wild type (+/+, WT), 52 C/EBPβ LIP homozygous (L/L) and 72 
C/EBPβ LIP heterozygous (+/L) mice were monitored over a period of more than 25 months. 
Protein analysis confirmed expression of C/EBPβ LIP in the same tissues as C/EBPβ in WT 
mice (Fig. 1a). Figure 1b illustrates the survival of +/L and L/L mice as compared to their WT 
siblings. Median survival for WT mice was 24 months, versus 20 months for +/L, and 17 
months for L/L mice. These results showed that deregulated expression of the C/EBPβ LIP 
isoform decreased survival in a dominant and dose-dependent manner. 
 
At 20 months of age, a 3.5-fold increase in tumorigenesis was observed in L/L mice as 
compared to WT littermates (Table 1 and Fig. 1c). Histopathological analyses of the solid 
tumors of L/L mice revealed B cell non-Hodgkin lymphoma (B-NHL, 25% in L/L vs 9% in 
WT), histiocytic sarcoma (HS, 5.8% in L/L vs 0% in WT) and lung adenocarcinoma (1.9% 
L/L vs 0% in WT) (Table 1 and Fig. S1). 
 
Mice that express one WT Cebpb allele and Cebpb LIP from the second allele (+/L) reflect 
translational deregulated, enhanced endogenous C/EBPβ LIP expression. At 20 months of 
age, 37.5% of the +/L mice had developed solid tumors, in comparison to 9% of the WT 
mice (Table 1 and Fig. 1c). Compared to L/L mice, the incidence of B-NHL was slightly 
increased in +/L (32% in +/L vs 25% in L/L), yet the incidence of histiocytic sarcoma and 
lung adenocarcinoma remained similar (histiocytic sarcoma: 7% in +/L vs 5.8% in L/L; lung 
adenocarcinoma: 1.4% in +/L vs 1.9% in L/L) (Table 1). A cohort of Cebpb heterozygous 
(Cebpb +/-) mice were kept under the same conditions. Median survival was similar in both 
Cebpb +/- and WT littermates (cohort: 25 Cebpb +/+ and 27 Cebpb +/- mice, median 
survival: 24 months and 25 months, respectively) and no tumor was found at 20 months of 
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age (data not shown). Investigation of spontaneous tumor formation in Cebpb -/- mice was 
not possible due to occurrence of infection and severe skin wound phenotype before one 
year of age in more than 60% of the mice. Altogether our data suggest that increase in 
C/EBPβ LIP is responsible for tumor development (as in +/L mice) but not a decrease in total 
C/EBPβ (as in Cebpb +/- mice).  
 
B-NHL was found at high incidence in the LIP ki mice. As shown in Figure 1d, LIP ki mice 
developed B-NHL significantly earlier than WT, although the 129 X C57BL/6 strain is known 
to be susceptible to B-NHL formation at old age [27]. Interestingly, expression of C/EBPβ, 
and in particular of the C/EBPβ LIP isoform, is high in lymphoma that develop in WT mice 
(Fig. 1e), in comparison to the spleens of young WT or LIP ki mice (Fig. 1a) and to the 
isolated CD19+ B cells (data not shown). Moreover the tumor spectrum in +/L mice was 
broader than that in L/L mice and included T-lymphoma, carcinoma of the skin, liver, and 
mammary gland (Table 1, Fig. 2, S2, S3 and S4). Note that C/EBPβ protein expression was 
detected in all tumor types (Fig. S1, S2 and S5). The generally low carcinoma incidence, 
however, may be masked by faster lymphoma development, as previously reported in other 
murine cancer models [28]. These data show that deregulated expression of C/EBPβ LIP 
from its own locus enhances tumor development in several mesenchymal and epithelial 
tissues. 
 
Deregulation of cancer pathways in LIP ki mice 
 
To determine which signaling pathways were altered in LIP ki mice tumors, B-NHL tumors 
obtained from LIP ki and WT mice were examined for cytogenetic alterations using SKY 
analysis (Table S1). No obvious gross genomic or recurrent rearrangements correlated with 
enhanced C/EBPβ LIP expression.  
 
Next, gene expression profiling analysis revealed 123 genes as differentially expressed in 
lymphoma of +/L mice in comparison to lymphoma of WT mice (Fig. 3a and Table S2; 66 
upregulated and 57 downregulated genes). Gene set enrichment analysis (GSEA) and 
examination of leading-edge gene subsets identified enrichment of C2 and C5 functional 
sets in +/L mice that belong to mTOR pathways (http://www.broadinstitute.org/gsea/msigdb). 
In addition to mTOR signaling, gene sets involved in translation and regulation of translation, 
mitochondrial function, metabolism, IGF1, and FOXO pathways, are all significantly enriched 
in lymphoma of +/L mice (Fig. 3b, c, d, e and Table S3). These data support the notion that 
elevated C/EBPβ LIP participates in metabolic signaling and mTOR regulated gene 
expression control during tumorigenesis.  
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In +/L lymphoma, GSEA highlighted 3 significant gene sets implicated in cell death signaling 
(Table S3). Moreover, the comparison between lymphoma of WT and +/L mice identified 
several gene sets involved in MAPkinase, ALK1, TGFβ, and NF-kB pathways that may affect 
apoptosis and that were significantly depleted in +/L lymphoma (Fig. S6 and Table S3). We 
also found that the number of apoptotic cells was slightly reduced in the spleen of +/L mice 
before tumor onset, whereas apoptosis rate was significantly increased in the spleen of 
Cebpb -/- compared to WT mice (Fig. 4a). Furthermore, reduction of caspase 3 cleavage 
was detected in CD19+ B cells and lymphoma from +/L, as compared to WT (Fig. 4b and 4c, 
respectively). Similar results were obtained with spleen and CD19+ B cells from L/L mice 
(data not shown). Altogether these data suggest that increase in C/EBPβ LIP expression 
reduced the apoptotic rate in B cells and B-NHL. 
 
Deregulation of immune defense might play a key role in tumorigenesis and several previous 
findings suggested C/EBPβ as an important transcription factor controlling cytokine and 
chemokine expression in immune cells. Deregulated gene expression comprised known 
C/EBPβ target genes, including Saa3, S100a9, Arg1, Fpr1, Cxcl13 (Table S2 and [29, 30]). 
Gene expression profiling showed that approximately 14% of the deregulated genes in +/L 
lymphoma encoded cytokines/chemokines (Fig. 5a and Table S2). Moreover, the 
comparison between lymphoma of WT and +/L mice using GSEA revealed leading-edge 
gene subsets involved in cytokine and chemokine biosynthesis, Toll-like receptor pathways, 
and innate immune response (Fig. 5b, c, d and Table S3). Expression levels of leukocyte 
recruiting Ccl3 and Ccl4 cytokines involved in tumor cell eradication, inflammatory M1 type 
classically activated macrophages (Cxcl13, Cxcl14, Cxcl16, Cx3cr1), and dendritic cells 
(Cxcl16, Cd11c) markers were all decreased in lymphoma of +/L mice (Fig. 5a). In contrast, 
M2 activated macrophage markers were enhanced in lymphoma of +/L mice (Fig. 5a; Cd36, 
Arg1, Ccl24, Mrc1, Retnla, Ccl11, Cd163). These data suggest association of a pro-
tumorigenic microenvironment in LIP ki lymphoma.  
 
Collectively, expression profiling and pathway analysis of C/EBPβ LIP lymphoma revealed 
an increase in pro-tumorigenic cytokine release, deregulation of chemokine expression and 
TLR signaling pathways, in addition to reduced apoptosis, that may all predispose and 
contribute to tumor susceptibility. This notion was further supported by recent evidence 
suggesting C/EBPβ as a critical regulator of myeloid derived suppressor cells that promote 
the pro-tumorigenic immunosuppressive microenvironment [31]. 
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To test whether deregulated C/EBPβ LIP expression promotes lympho/myelo-proliferation 
we performed bone marrow (BM) transfer of WT cells into lethally irradiated WT or L/L 
recipient mice (Fig. S7A). The distribution of hematopoietic cell lineages was different in WT 
BM reconstituted L/L and WT mice although engraftment of donor cells and the spleen 
weights were similar in both recipient strains (Fig. S7B and C). An increase in myeloid cells 
(CD11b positive cells) and a decrease in T cells (CD3 positive cells) were found in the 
spleens of WT BM reconstituted L/L mice, in comparison to WT BM reconstituted WT mice 
(B220 positive cells were not affected; Fig. S7D). In peripheral blood, white blood cells 
(granulocytes, monocytes, lymphocytes) of WT donor origin were higher in L/L than in WT 
recipient mice (Fig. S7E and F), but no changes in red blood cell counts were observed (Fig. 
S7G). These data suggest that enhanced expression of the C/EBPβ LIP isoform facilitates a 
tumor supportive microenvironment, but further experiments are required to determine how 
the microenvironment is actually altered in LIP mice.  
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Discussion 
 
Data shown here firmly establish the proto-oncogenic function of endogenous C/EBPβ LIP in 
mesenchymal and epithelial tissues. Tumors were found in tissues previously shown to 
depend on C/EBPβ functions, including mammary gland, skin, liver, lung, and hematopoietic 
cells [15, 16, 30 , 32-34]. Enhanced C/EBPβ LIP expression leads to the development of 
follicular lymphoma (B-NHL) and histiocytic sarcoma. Human follicular lymphoma may 
eventually trans-differentiate into histiocytic sarcoma and C/EBPβ was found to be strongly 
expressed in these tumors [35]. C/EBPβ LIP has also been shown to promote proliferation of 
human B cell Hodgkin lymphoma and ALCL [14, 16], suggesting an important function of 
C/EBPβ LIP deregulation in lymphomagenesis and hinting at similarities in disease 
development in rodents and human. 
 
C/EBPβ LIP is thought to antagonize the long isoforms C/EBPβ LAP*/LAP, other C/EBP 
members, and some bZIP factors [36, 37]. Accordingly, four scenarios can be envisioned to 
describe the effect of C/EBPβ LIP on gene expression: (i) C/EBPβ LIP acts alone, (ii) 
C/EBPβ LIP antagonizes other C/EBP family members or bZIP factors, (iii) C/EBPβ LIP 
antagonizes the LAP*/LAP isoforms of C/EBPβ or (iv) ii and iii at the same time.  C/EBPβ 
LIP heterozygous mice can reflect all four modes of action while L/L mice can affect (i) and 
(ii) but not (iii) and (iv). C/EBPβ LIP heterozygous mice develop a broader tumor spectrum 
and higher percentage of tumor incidence than L/L mice, suggesting that the oncogenic 
action of C/EBPβ LIP is mediated through antagonism of the C/EBPβ LAP*/LAP isoforms. 
However, L/L mice die significantly earlier than +/L mice and tumor types that might develop 
later in life (e.g. requiring more oncogenic events) will not be found in L/L mice. Similarly, 
analysis of spontaneous tumor formation in p53 deficient mice showed a wider tumor 
spectrum in p53 +/- mice as compared to p53 -/- mice [28]. These data suggests that 
dosage effects of oncogenes or tumor suppressor genes may affect tumor development. 
Carcinogen-induced tumorigenesis in LIP ki mice or combination with other murine 
oncogenic models will help to resolve the underlying molecular events in future experiments. 
Surprisingly and in contrast to the Cebpb -/- mice, L/L and +/L mice both do not show skin 
phenotypes, loss of hair or reduced fat content (data not shown), suggesting that C/EBPβ 
LIP isoform functions are not reflecting simple loss of function phenotypes and go beyond 
inhibition of C/EBPβ LAP*/LAP or other C/EBPs members in the skin or fat. These 
observations support the notion that regulatory capacity by C/EBPβ LIP is context 
dependent and more complex that the four possibilities of action, as noted above. 
Nevertheless, it was important to first analyze spontaneous tumor formation in LIP ki mice 
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and here, our data revealed the oncogenic potential of C/EBPβ LIP from its own locus in 
divers tissues. 
 
The long latency of tumor development in LIP ki mice suggests that additional oncogenic 
events are required in conjunction with C/EBPβ LIP deregulation. Co-operation of several 
proto-oncogenes and loss of tumor suppressor functions is a common explanation of tumor 
development. However, tumorigenesis was not accelerated in compound mice heterozygous 
for p53 deletion and C/EBPβ LIP deregulation, as compared to p53 heterozygous mice (data 
not shown). It therefore remains to be resolved which additional oncogenic events may 
accelerate tumor development in +/L or L/L mice.  
 
The GSEA analyses indicated several altered pathways in lymphoma of LIP ki mice that 
relate to autonomous and non-cell autonomous effects on B cell lymphomagenesis. The 
structural features of Cebpb gene (lack of introns), however, render a conditional genetic 
approach rather difficult to experimentally resolve how C/EBPβ LIP supports oncogenesis. In 
contrast to Cebpa, no mutational alterations within the Cebpb coding region that affect the 
isoform expression have yet been reported. However, deregulation of C/EBPβ LIP 
expression may occur on the signaling/proteomic, rather than on the genomic level. In any 
case, our results show that tight regulation of the balance between long and truncated 
C/EBPβ isoforms is important for preventing tumor formation. Accordingly, the data imply 
that translational deregulation may dysbalance C/EBPβ isoform expression to contribute to 
tumorigenesis.  
 
Previously, we have shown that the mTOR-TORC1 inhibitor rapamycin restricts upregulation 
of C/EBPβ LIP expression and lymphoma xenograft growth [3, 14]. Moreover, a translational 
control defective C/EBPβ mutant phenocopied mTOR inhibition and mTOR target genes 
were found to be co-regulated by C/EBPβ and thus identified C/EBPβ as an important 
mediator of mTOR functions [9, 10]. Activation of mTOR promotes protein biosynthesis, 
translation reinitiation, M2 polarization, cell survival, and tumorigenesis, [38, 39]. 
Deregulated mTOR signaling is evident in lymphomagenesis and leukemogenesis and 
development of therapeutic strategies based on mTOR inhibition are currently under 
investigation [40, 41]. Lymphoma cells of C/EBPβ LIP heterozygous mice showed 
enrichment of rapamycin sensitive genes, including FABP4 and adipokines that are thought 
to play an important role in tumorigenesis [42]. In addition, eIF-4E, a key factor of translation 
initiation that is regulated by the mTOR sensitive 4EBPs also up-regulates C/EBPβ LIP 
expression and promotes neoplasia [3, 43]. Our data therefore imply that pharmacologic 
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interference with uORF mediated C/EBPβ LIP translation initiation control may help to re-
establish the balance between C/EBPβ isoforms and oppose deregulated mTOR signaling. 
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Figure legends 
 
Fig. 1 LIP ki mice are cancer prone. (a). C/EBPβ isoform expression in tissues of WT and 
LIP ki mice. Various tissues isolated from 8-week-old WT and LIP ki mice (+/L, L/L) were 
lysed in 8 M urea lysis buffer and analyzed by Western blotting for expression of C/EBPβ 
isoforms LAP*, LAP and LIP (as indicated). M.GL.: mammary gland; WAT: white adipose 
tissue; BAT: brown adipose tissue; Pan: pancreas; BM: bone marrow. 3T3-L1 cells (L1) and 
C/EBPα -/- MEF (α-/-) were used as positive controls whereas C/EBPβ -/- MEF (β-/-) were 
used as negative controls. α-tubulin was used as internal control. White asterisk (*): 
unspecific immune reactivity. (b) Dosage effect of C/EBPβ LIP on survival rate. Kaplan-
Meier curve of +/+ (black line) and LIP ki mice (+/L, orange line; L/L, green line) housed over 
a period of 25 months. Mice were monitored twice weekly for tumor formation. Moribund 
mice or mice showing fatal illness or tumor development were sacrificed and tissues were 
isolated for further examination. Cohorts of mice: +/+ n= 45; +/L n = 72; L/L n = 52. 
Accelerated death of +/L and L/L mice versus +/+ mice, and of +/L mice versus L/L mice 
according to the Log-rank test was significant in each case: ***P< 0.0001. (c) Comparison of 
survival rate and tumor incidence at 20 months of age between LIP ki mutants and WT mice: 
+/+ (4 tumors out 45 +/+ mice); +/L (27 tumors out of 72 mice); L/L (16 tumors out of 52 
mice). (d) Comparison of average age for lymphoma development in WT and LIP ki mice. 
Cohorts of mice: +/+ n= 45; +/L n = 72; L/L n = 52. Error bars show SEM. Significant 
accelerated lymphoma development of +/L and L/L mice versus +/+ mice were analyzed 
using the unpaired two-tailed Mann-Whitney’s test: ***P< 0.0001. (e) Lymphoma found in 
WT and LIP ki mice were lysed in 8 M urea lysis buffer and analyzed by Western blotting for 
expression of C/EBPβ isoforms LAP*, LAP and LIP (as indicated). β-tubulin was used as 
internal control. 
 
Fig. 2 LIP ki mice develop mesenchymal and epithelial tumors. Histological analysis (H&E 
staining) of mesenchymal (a and c) and epithelial (d-h) tumors found in the +/L mice. (a-b) B 
cell non-hodgkin lymphoma (B-NHL, a) with massive infiltration of B cells in the liver (arrows 
in a) characterized by B220 immunopositive staining (arrows in b). See Fig. S1 for further 
characterization of the B-NHL. (c) A histiocytic sarcoma with nodular infiltrates (arrows) 
developed in the spleen. See Fig. S2 for further characterization of the histiocytic sarcoma. 
(d) Liver with a hepatocellular carcinoma (HCC) showing a trabecular growth pattern 
(arrow). Arrowhead: mitotic figure. (e-f) A ductal (e) and a tubular (f) mammary carcinoma 
developed in a +/L female of 16 months of age. (g) Skin carcinoma with squamous 
differentiation and keratinization (arrowhead) as well as horn pearl formation (arrow). (h) 
Lung adenocarcinoma with papillary growth pattern. a, b: scale bar = 25 µm; c, d, g, h: scale 
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bar = 20 µm; e, f: scale bar = 10 µm. See Fig S3 and S4 for comparison with non-tumor 
tissues from age-matched +/+ mice. 
 
Fig. 3 Gene expression profiling analysis of B-NHL of LIP ki mice. (a) Heat map of 
differentially regulated genes in B-NHL of +/L mice in comparison to B-NHL of WT mice as 
identified by gene array analysis. +/+ n = 5; +/L n = 5, See list of the genes in Table S2. (b-e) 
GSEA based on the comparison of B-NHL of +/L and WT mice for enrichment or depletion of 
rapamycin sensitive genes (b), translation (c), FOXO pathway (d) and oxidative 
phosphorylation and TCA cycle and respiratory electron transport (e) associated genes. The 
normalized enrichment scores (NES) and P values are indicated in each plot. Note the 
positive NES values observed in all cases indicating an upregulation of these gene sets in B-
NHL of +/L mice compared to B-NHL of WT mice. 
 
Fig. 4 Impaired apoptosis in LIP ki mice before and after tumor onset. (a). Number of 
apoptotic cells in the splenic white pulp of C/EBPβ mutants and WT mice before tumor 
onset. Apoptotic cells were analyzed using cleaved-caspase 3 immunostaining. Numbers of 
positive cleaved-caspase 3 cells/field were counted and expressed as fold of control. n = 5 
per genotype. Error bars show SEM. *P<0.05. (b-c). Representative immunoblot analyses 
showing decrease in cleaved-caspase 3 (Cl.caspase 3) expression in CD19+ B cells sorted 
from spleen of 12 months-old LIP ki mice as compared with those of WT counterparts (b) 
and in B-NHL of LIP ki mice as compared with B-NHL of WT mice (c). β-tubulin was used as 
loading control. The CD19+ B cells samples were run on the same gel, but were 
noncontiguous (same for B-NHL samples).  
 
 
Fig. 5 Deregulated C/EBPβ LIP expression altered cytokines and chemokines expression 
levels in B-NHL of LIP ki mice. (a) Heat map showing deregulated expression of cytokines 
and chemokines in B-NHL of +/L mice in comparison to B-NHL of WT mice. +/+ n = 5; +/L n 
= 5. (b-d) GSEA based on the comparison of B-NHL of +/L and WT mice for enrichment or 
depletion of regulation of cytokine biosynthetic process (b), Toll like receptor signaling 
pathway (c), and innate immune system (d) associated-genes. The normalized enrichment 
scores (NES) and P values are indicated in each plot. Note the negative NES values 
observed in all cases indicating a depletion of these gene sets in B-NHL of +/L mice 
compared to B-NHL of WT mice. 
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TABLES 
 
Table 1 Tumor distribution in LIP ki mice at 20 months of age. 
Genotype +/+ +/L L/L 
Number dead/cohort 11/45 41/72 44/52a 
Tumor incidence:     
/cohort 4/45 (9%) 27/72 (37.5%)*** 16/52 (30.8%)** 
/number dead 4/11 (36%) 27/41 (66%)* 16/44 (36%) 
B-NHL 4/45 (9%) 23/72 (32%) 13/52 (25%) 
T-lymphoma 0 1/72 0 
Histiocytic sarcoma 0 5/72 3/52 
Mammary gland 
carcinoma 0 2/72 0 
HCC 0 1/72 0 
Skin carcinoma 0 1/72 0 
Lung tumor 0 1/72 1/52 
 
Note that some mice developed multiple primary solid tumors. Tumor incidence reflects 
number of mice with any kind of tumor(s) even though an animal might develop more than 
one tumor. B-NHL: B non-Hodgkin lymphoma, HCC: hepatocellular carcinoma.  
Unpaired t test: *P<0.02; **P<0.005; ***P<0.0005. 
aL/L mice show a high death rate but a lower tumor incidence in comparison to +/L mice. L/L 
mice developed more infection and abscess than +/L and +/+ mice.  
 
 



+/+ +/L
 
β -/-0.0
0.5
1.0
1.5
3
4 *
ap
op
to
tic
 c
el
ls
(fo
ld
 o
f c
on
tro
l)
b
+/+
+/+
+/L
+/L
a
c
β-tubulin
β-tubulin
cl. caspase 3
cl. caspase 3

 1 
Journal of Molecular Medicine 
 
SUPPLEMENTARY MATERIAL 
 
Deregulation of the endogenous C/EBPβ LIP isoform predisposes to 
tumorigenesis 
 
Valérie Bégay, Jeske J. Smink, Christoph Loddenkemper, Karin Zimmermann, 
Cornelia Rudolph, Marina Scheller, Doris Steinemann, Ulf Leser, Brigitte 
Schlegelberger, Harald Stein and Achim Leutz. 
 
Corresponding author: Achim Leutz, Univ.-Prof. Dr. rer. nat., Max Delbrueck Center 
for Molecular Medicine, Dept of Tumorigenesis and Cell Differentiation, Robert-
Roessle-Str.10, 13125 BERLIN Germany. Phone: + 49 30 9406 3735, Fax: + 49 30 
9406 3298, Email: aleutz@mdc-berlin.de.  
 
 
 
SUPPLEMENTARY METHODS 
 
Animals. C57BL/6 Ly5.1 (carrying the CD45.1 marker, also called B6-SJL) congenic 
mice were originally obtained from Charles River Laboratoires, crossed to 129-Ola 
(carrying the marker CD45.2) mice to generate 129 X C57BL/6 (CD45.1/CD45.2, 
called B6-SJL;129-Ola) mice used as donors for bone marrow (BM) cell 
transplantation. Four to 5 months-old WT and L/L recipient mice (CD45.2) were kept 
on 129 X C57BL/6 genetic background. 
 
Mouse transplantation experiments. Freshly isolated BM cells were injected (2 X 
106 cells/mouse) through the tail vein into lethally irradiated (9.5-10 Gy total body 
irradiation, Cs-137 source) WT or L/L recipient mice. Six weeks after transplantation, 
repopulation/engraftment was determined and then every 4 weeks by collection of 
peripheral blood, erythrocyte lysis, and staining of CD45.1 and CD45.2. 
 
Immunohistochemistry (IHC) and analysis. Detection of C/EBPβ (C19, Santa 
Cruz), Ki67 (Tec-3; Dako), CD3 (n° 1580; Dako); Pax5 (24, Transduction 
Laboratories), or F4/80 (eBioscience) was performed in paraffin embedded tissue as 
 2 
described in the manuscript. Binding of the antibodies was detected by Envision 
peroxidase kit (K4010, Dako) using diaminobenzidine as chromogenic substrate or 
by the streptavidin alkaline phosphatase kit (K5005, Dako). Note that the rabbit 
C/EBPβ antibody (C19, Santa cruz) recognizes the C-terminal part of C/EBPβ 
therefore all isoforms.  
 
Cell preparation, FACS analysis and CD19+ B cells sorting. Bone marrow (BM) 
cell suspensions were prepared by flushing femurs and tibias with PBS. Single-cell 
suspensions were prepared from 2/3 of the spleen dissected from 12 or 13-month-
old mice, and histopathology analysis was performed on the third part of the spleen 
as described in the manuscript. Spleen cell suspensions were obtained by gentle 
disruption of the organ through a cell strainer (70µm, BD Falcon) in PBS/2% fetal calf 
serum. Peripheral blood (PB) samples were obtained from the tail vein and collected 
into EDTA coated tubes. The blood cell counts were measured with an automated 
veterinary hematological counter Scil Vet abc (SCIL GmbH, Viernheim, Germany), 
with software optimized for mouse blood parameters. Red blood cells (RBC) were 
lysed on ice with hypotonic erythrocyte lysis buffer (BD Pharmlyse buffer). Non 
specific binding was reduced by preincubation with unconjugated antibody to 
FcγRII/III (2.4G2, BD PharmingenTM) prior to labeling in FACS buffer (PBS, 0,5% 
BSA, 2mM EDTA). Dead cells were excluded by propidium iodide or 7-AAD staining. 
Cell staining and sorting were performed using fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), allophycocyanin (APC) labeled monoclonal antibodies directed 
against CD45.1 (A20), CD45.2 (104), B220 (6B2), CD19 (1D3), CD3 (KT31.1) and 
Mac1/CD11b (M1/70) (BD Biosciences, eBioscience and Biolegend). Cells were 
sorted on FACS ARIA and data were acquired on a LSRII flow cytometers (Becton 
Dickinson), and were further analyzed with FlowJo software (TreeStar). 
 
Spectral karyotyping. Metaphase chromosomes were prepared by treating cells 
with colcemid at a final concentration of 0.035 µg/ml overnight, incubated in 0.075 M 
KCL for 20 min at 37°C and fixed in a freshly prepared mixture of methanol:acetic 
acid (3:1) at room temperature. Cell suspension was dropped onto glass slides in a 
climate chamber (Polymer, Kassel, Germany) at 22°C and 48% humidity. Spectral 
karyotyping (SKY) was performed as described previously (1) and according to the 
manufacturer’s instructions (ASI: Applied Spectra Imaging, Ltd., Migdal HaEmek, 
Israel). Spectral images were acquired using an epifluorescence microscope 
equipped with an interferometer (SpectraCubeTM ASI), a custom-designed optical 
filter and the SkyViewTM software (ASI). 
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Fig S3. Histological analysis (H&E staining) of hematopoietic (B, D) and epithelial (F, H 
and J) tumors found in +/L mice in comparison with control tissues from age-matched 
WT mice (A, C, E, G and I) at low magnification. (A) Liver with normal parenchyma (p), 
vein (asterisk). (B) Liver with massive infiltration of B cells (arrows), vein (asterisk) (C) 
Normal splenic architecture with white pulp (WP), red pulp (RP) and trabeculae (arrows). 
(D) Histiocytic sarcoma with nodular infiltrates (arrows) developed in the spleen. (E) 
Mammary gland fad pad with normal epithelium duct (arrows), lymph node (asterisk) and 
vessel (v). (F) Mammary carcinoma developed in mammary fat pad (arrows). (G) Normal 
lung parenchyma with bronchiole (arrowheads) and alveoli (asterisks). (H) Lung 
adenocarcinoma with papillary growth. (I) Normal skin architecture with epidermis (e), 
dermis (d), hair follicle (HF) and muscle (m). (J) Skin carcinoma with squamous 
differentiation and keratinization (arrowheads). T: tumor tissue; N: normal tissue. 
Magnification x5 for all micrographs. 
 

Fig S4. Histological analysis (H&E staining) of hematopoietic (B, C, E) and epithelial (G, 
I, J, L and N) tumors found in +/L mice in comparison with counterpart tissues from 
aged-matched WT mice (A, D, F, H, K and M) at higher magnification. (A) Liver with 
normal parenchyma (p). (B, C) B-NHL with massive infiltration of B cells in the liver 
(arrows in B) characterized by B220 immunopositive staining (arrows in C). (D) Normal 
splenic architecture with white pulp (WP), red pulp (RP) and trabeculae (arrow). (E) 
Histiocytic sarcoma with nodular infiltrates (arrows) developed in the spleen. (F) Liver 
with normal parenchyma (p). (G) Liver with a hepatocellular carcinoma (HCC) showing a 
trabecular growth pattern (arrow) (arrowhead: mitotic figure). (H) Mammary gland fad 
pad with normal epithelium duct (arrows). (I) A ductal and (J) a tubular mammary 
carcinoma developed in mammary fat pad of a +/L female. (K) Normal skin architecture 
with hair follicle (HF) and adipocytes (a). (J) Skin carcinoma with squamous 
differentiation and keratinization (arrowhead) and horn pearl formation (arrow). (M) 
Normal lung parenchyma with bronchiole (arrowheads) and alveoli (asterisk). (N) Lung 
adenocarcinoma with papillary growth. p: parenchyma; v: vein. A, B, C: scale bar = 25 
µm; D-G, K-N: scale bar = 20 µm; H-J: scale bar = 10 µm. 
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Fig S7. C/EBPβ LIP niche alters hematopoietic cell distribution in the peripheral blood and spleen. (A) Schematic representation of the transplantation 
strategy. Total bone marrow cells (2 X 106) from B6-SJL;129-Ola mice (carrying the CD45.1 and CD45.2 markers) were transplanted into lethally 
irradiated WT or L/L recipient mice (carrying CD45.2 marker). Recipients were sacrificed 33 weeks after transplantation and the hematopoietic cells of 
the peripheral blood (PB) and spleen were analyzed by FACS. (B) Engraftment of the donor cells (CD45.1+/CD45.2+ cells) in the spleen and periph-
eral blood (PB). (C) Ratio of spleen weight versus body weight. (D) Distribution of myeloid cells (CD11b+ marker), T cells (CD3+ marker) and B cells 
(B220+ marker) in the spleen. (E) White blood cell (WBC) count measured in the peripheral blood. (F) Distribution of granulocytes, monocytes and 
lymphocytes measured in the peripheral blood. (G) Red blood cell (RBC) count, hematocrit (HCT) and hemoglobin (HGB) levels measured in the 
peripheral blood. All graphs represent the +/+ (grey bar) and L/L mice (green bar). n = 5 per genotype. Error bars show SEM. *P<0.05. ***P< 0.001. 
Table S1. SKY analysis of B-NHL isolated from LIP ki mice. 
 
Genotype Tissuea Karyotypesb 
+/+ spleen 40, XX [9] 
+/+ spleen 41-43, XX, +14, +15, +17 [cp5]/ 
40, XX [10] 
+/+ spleen 41, XX, +15 [4]/ 
41, XX, +17 [2]/ 
42, XX, +15, +17 [1]/ 
40, XX [8] 
   
+/L LN 40, XX [10] 
+/L LN 40, XX [8] 
+/L spleen 40, XX [10] 
   
L/L LN 41, XX, +X [3]/ 
41, XX, +X, ?Del(19) [cp6]/ 
40, XX [5] 
L/L LN 80<4n>, XXXX [3]/ 
40, XX [11] 
L/L spleen 40, XX [6]/ 
80<4n>, XXXX [8] 
L/L spleen 40, XX [9] 
 
No chromosomal alterations were observed in 3 analyzed +/L lymphomas. Tetraploid 
chromosomal complements were seen in L/L lymphomas. Note that 2 out of 3 
analyzed lymphomas found in WT carried a trisomy 15 and 17 as clonal 
chromosomal alterations. B-NHL: B non-Hodgkin’s lymphoma. a LN: lymph node; b 
Del: deletion, [n]: number of metaphases showing the alteration, [cp]: composite 
karyotype. Clonal chromosomal alterations are marked in bold. 
 
Table S2. List of deregulated genes in B-NHL of +/L mice.
Symbol log2(fc) P value GeneName
Cfd 3,47 1,72E-02 complement factor D (adipsin)
S100a9 2,89 9,94E-03 S100 calcium binding protein A9 (calgranulin B)
Ccl24 2,78 9,40E-03 chemokine (C-C motif) ligand 24
Htatip2 2,41 1,50E-04 HIV-1 tat interactive protein 2, homolog (human)
Lum 2,32 1,48E-02 lumican
Igfbp5 2,15 8,20E-04 insulin-like growth factor binding protein 5
Cidec 2,13 1,81E-02 cell death-inducing DFFA-like effector c
Postn 2,09 1,56E-02 periostin, osteoblast specific factor
Glycam1 2,09 1,33E-02 glycosylation dependent cell adhesion molecule 1
Retnla 1,99 1,93E-02 resistin like alpha
Mrc1 1,84 8,44E-03 mannose receptor, C type 1
Aldh1a2 1,67 9,40E-04 aldehyde dehydrogenase family 1, subfamily A2
Fabp4 1,62 9,74E-03 fatty acid binding protein 4, adipocyte
Rab15 1,62 1,16E-02 RAB15, member RAS oncogene family
Adipoq 1,58 4,06E-02 adiponectin, C1Q and collagen domain containing
Arg1 1,57 2,35E-02 arginase, liver
Cpe 1,56 3,84E-03 carboxypeptidase E
Plin4 1,52 7,32E-03 perilipin 4
Cbr2 1,48 1,76E-02 carbonyl reductase 2
Fabp7 1,47 1,34E-02 fatty acid binding protein 7, brain
Saa3 1,45 2,11E-02 serum amyloid A 3
Fam103a1 1,45 2,00E-05 family with sequence similarity 103, member A1
Malat1 1,39 3,95E-03 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)
Cma1 1,33 5,75E-03 chymase 1, mast cell
Fus 1,33 2,60E-04 fusion, derived from t(12;16) malignant liposarcoma (human)
Clec2d 1,30 1,98E-02 C-type lectin domain family 2, member d
Cfh 1,30 2,21E-02 complement component factor h
Ccl11 1,29 8,54E-03 chemokine (C-C motif) ligand 11
Cd163 1,27 6,44E-03 CD163 antigen
BC018465 1,25 1,59E-03 cDNA sequence BC018465
Aldh1a3 1,25 1,30E-02 aldehyde dehydrogenase family 1, subfamily A3
Gadd45g 1,25 1,79E-03 growth arrest and DNA-damage-inducible 45 gamma
Madcam1 1,25 1,13E-02 mucosal vascular addressin cell adhesion molecule 1
Il33 1,24 1,55E-02 interleukin 33
Gas6 1,23 3,08E-03 growth arrest specific 6
Plin1 1,23 3,71E-02 perilipin 1
Dpt 1,22 3,16E-03 dermatopontin
Fam174b 1,21 1,10E-02 family with sequence similarity 174, member B
Hdc 1,19 6,75E-03 histidine decarboxylase
Metrn 1,17 3,00E-05 meteorin, glial cell differentiation regulator
Folr2 1,16 3,46E-02 folate receptor 2 (fetal)
Surf6 1,15 3,00E-05 surfeit gene 6
Dnajc7 1,14 1,96E-03 DnaJ (Hsp40) homolog, subfamily C, member 7
Snord123 1,13 3,18E-03 small nucleolar RNA, C/D box 123
Hbb-bh1 1,13 3,96E-02 hemoglobin Z, beta-like embryonic chain
Figf 1,11 6,84E-03 c-fos induced growth factor
Echdc2 1,10 4,59E-02 enoyl Coenzyme A hydratase domain containing 2
Agt 1,09 3,01E-02 angiotensinogen (serpin peptidase inhibitor, clade A, member 8)
Scgb3a1 1,09 1,71E-02 secretoglobin, family 3A, member 1
Mcpt4 1,09 1,35E-02 mast cell protease 4
Ppp3ca 1,08 3,00E-05 protein phosphatase 3, catalytic subunit, alpha isoform
Themis 1,08 1,96E-02 thymocyte selection associated
Hsd11b1 1,06 4,96E-02 hydroxysteroid 11-beta dehydrogenase 1
Nkx2-3 1,05 1,06E-02 NK2 transcription factor related, locus 3 (Drosophila)
Cyfip1 1,04 8,31E-03 cytoplasmic FMR1 interacting protein 1
Prmt1 1,04 1,82E-03 protein arginine N-methyltransferase 1
Atp1a2 1,04 5,02E-03 ATPase, Na+/K+ transporting, alpha 2 polypeptide
Tmed9 1,03 2,30E-04 transmembrane emp24 protein transport domain containing 9
1500012F01Rik 1,03 2,20E-04 RIKEN cDNA 1500012F01 gene
The Symbol and the annotation of the genes are shown. The fold of change (log2(fc)) and the P value 
are indicated for each gene. 
Symbol log2(fc) P value GeneName
C6 1,03 7,51E-03 complement component 6
Ly9 1,01 1,00E-04 lymphocyte antigen 9
Cd36 1,01 3,15E-02 CD36 antigen
Vapb 1,01 7,10E-03 vesicle-associated membrane protein, associated protein B and C
Cited4 1,01 3,70E-02 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4
Ces3 1,01 4,37E-03 carboxylesterase 3
Cox6c 1,01 0,00E+00 cytochrome c oxidase, subunit VIc
Tlr2 -1,00 1,03E-03 toll-like receptor 2
Rnd3 -1,00 2,06E-02 Rho family GTPase 3
9830001H06Rik -1,00 9,30E-04 RIKEN cDNA 9830001H06 gene
1700112E06Rik -1,00 3,26E-03 RIKEN cDNA 1700112E06 gene
D6Mm5e -1,01 2,04E-02 DNA segment, Chr 6, Miriam Meisler 5, expressed
Lpcat2 -1,02 1,40E-03 lysophosphatidylcholine acyltransferase 2
Pigz -1,02 1,37E-03 phosphatidylinositol glycan anchor biosynthesis, class Z
Tm6sf2 -1,02 4,73E-02 transmembrane 6 superfamily member 2
Hist1h2ak -1,03 5,90E-04 histone cluster 1, H2ak
Nr1h3 -1,04 4,06E-02 nuclear receptor subfamily 1, group H, member 3
Abhd2 -1,05 1,23E-03 abhydrolase domain containing 2
Zmynd15 -1,06 2,79E-03 zinc finger, MYND-type containing 15
Hist1h1e -1,06 6,14E-03 histone cluster 1, H1e
Niacr1 -1,08 1,43E-03 niacin receptor 1
Hist1h2ai -1,08 4,30E-04 histone cluster 1, H2ai
Cxcl16 -1,10 3,26E-03 chemokine (C-X-C motif) ligand 16
Nosip -1,11 1,66E-03 nitric oxide synthase interacting protein
C1qa -1,11 3,91E-02 complement component 1, q subcomponent, alpha polypeptide
Fcer1g -1,12 2,96E-02 Fc receptor, IgE, high affinity I, gamma polypeptide
8430428J23Rik -1,13 4,71E-02 RIKEN cDNA 8430428J23 gene
Hyi -1,14 7,62E-03 hydroxypyruvate isomerase homolog (E. coli)
Ltbp2 -1,15 1,14E-02 latent transforming growth factor beta binding protein 2
Kcnj10 -1,15 1,01E-03 potassium inwardly-rectifying channel, subfamily J, member 10
Gdf3 -1,17 1,24E-02 growth differentiation factor 3
Lsm14b -1,18 8,00E-05 LSM14 homolog B (SCD6, S. cerevisiae)
Batf2 -1,19 1,20E-02 basic leucine zipper transcription factor, ATF-like 2
Lst1 -1,19 6,64E-03 leukocyte specific transcript 1
Smpdl3b -1,19 1,41E-03 sphingomyelin phosphodiesterase, acid-like 3B
Fam20c -1,20 4,19E-02 family with sequence similarity 20, member C
Klra17 -1,20 8,30E-04 killer cell lectin-like receptor, subfamily A, member 17
Cap1 -1,21 1,67E-03 CAP, adenylate cyclase-associated protein 1 (yeast)
Rdh12 -1,23 4,92E-02 retinol dehydrogenase 12
Il28ra -1,23 2,64E-02 interleukin 28 receptor alpha
H28 -1,26 1,54E-02 histocompatibility 28
Cxcl13 -1,27 4,92E-02 chemokine (C-X-C motif) ligand 13
C1qb -1,27 1,47E-02 complement component 1, q subcomponent, beta polypeptide
1810033B17Rik -1,28 1,51E-02 RIKEN cDNA 1810033B17 gene
Clec4a3 -1,29 3,01E-02 C-type lectin domain family 4, member a3
Cx3cr1 -1,37 1,80E-03 chemokine (C-X3-C) receptor 1
Prim2 -1,37 1,06E-02 DNA primase, p58 subunit
Fpr2 -1,38 3,73E-02 formyl peptide receptor 2
Slc11a1 -1,40 3,65E-03 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1
Fpr1 -1,42 8,82E-03 formyl peptide receptor 1
Itgax -1,42 1,53E-02 integrin alpha X
Ccl4 -1,45 7,46E-03 chemokine (C-C motif) ligand 4
Actg2 -1,46 6,00E-05 actin, gamma 2, smooth muscle, enteric
Asb2 -1,48 5,24E-03 ankyrin repeat and SOCS box-containing 2
Ifi202b -1,59 1,38E-02 interferon activated gene 202B
Kif1a -1,60 5,00E-05 kinesin family member 1A
Ccl3 -1,61 3,36E-03 chemokine (C-C motif) ligand 3
Rmrp -1,65 4,00E-05 RNA component of mitochondrial RNAase P
Cxcl14 -1,84 7,60E-04 chemokine (C-X-C motif) ligand 14
Serpina1d -1,88 1,55E-03 serine (or cysteine) peptidase inhibitor, clade A, member 1D
Sostdc1 -1,89 4,94E-03 sclerostin domain containing 1
Serpina1c -2,00 5,70E-04 serine (or cysteine) peptidase inhibitor, clade A, member 1C
Serpina1b -2,19 1,52E-03 serine (or cysteine) preptidase inhibitor, clade A, member 1B
1810009J06Rik -2,35 5,10E-04 RIKEN cDNA 1810009J06 gene
Table S3. GSEA of deregulated genes found in B-NHL of +/L mice.
human C2 negative report
GENE SET NAME SIZE NES NOM p-val FDR q-val
KEGG_THYROID_CANCER 25 -2,222 0,000 0,021
KEGG_LEISHMANIA_INFECTION 47 -2,165 0,000 0,030
PID_IL27PATHWAY 25 -2,154 0,000 0,023
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 90 -2,125 0,000 0,022
REACTOME_PLATELET_SENSITIZATION_BY_LDL 16 -2,045 0,000 0,043
SA_MMP_CYTOKINE_CONNECTION 15 -2,040 0,000 0,038
BIOCARTA_IL12_PATHWAY 21 -1,977 0,003 0,064
REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_
FACTOR_ACTIVATION
23 -1,911 0,000 0,102
BIOCARTA_NTHI_PATHWAY 23 -1,887 0,000 0,110
BIOCARTA_NO2IL12_PATHWAY 15 -1,885 0,000 0,100
BIOCARTA_IL6_PATHWAY 20 -1,884 0,006 0,093
PID_IL23PATHWAY 35 -1,879 0,000 0,088
REACTOME_ERK_MAPK_TARGETS 20 -1,878 0,000 0,082
PID_ALK1PATHWAY 24 -1,877 0,003 0,077
PID_RXR_VDR_PATHWAY 24 -1,875 0,000 0,074
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 87 -1,857 0,000 0,080
REACTOME_GLYCOLYSIS 23 -1,854 0,000 0,077
BIOCARTA_NKT_PATHWAY 29 -1,849 0,004 0,075
BIOCARTA_TGFB_PATHWAY 18 -1,819 0,000 0,091
BIOCARTA_DC_PATHWAY 22 -1,804 0,003 0,099
BIOCARTA_FMLP_PATHWAY 33 -1,786 0,000 0,108
KEGG_GRAFT_VERSUS_HOST_DISEASE 16 -1,783 0,009 0,106
KEGG_NOTCH_SIGNALING_PATHWAY 39 -1,772 0,000 0,111
REACTOME_ACTIVATED_TLR4_SIGNALLING 77 -1,769 0,000 0,109
BIOCARTA_HCMV_PATHWAY 17 -1,747 0,007 0,124
BIOCARTA_P38MAPK_PATHWAY 37 -1,736 0,008 0,129
REACTOME_TOLL_RECEPTOR_CASCADES 94 -1,715 0,000 0,144
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_
BY_TLR4_SIGNALING_REPERTOIRE
60 -1,713 0,000 0,140
SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES 47 -1,710 0,008 0,138
REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY
_MAP_KINASES
29 -1,705 0,007 0,138
KEGG_CHRONIC_MYELOID_LEUKEMIA 69 -1,684 0,000 0,157
REACTOME_RNA_POL_I_PROMOTER_OPENING 23 -1,681 0,007 0,155
PID_FCER1PATHWAY 54 -1,679 0,000 0,153
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING 71 -1,675 0,000 0,153
BIOCARTA_IL2_PATHWAY 20 -1,666 0,019 0,159
ST_T_CELL_SIGNAL_TRANSDUCTION 43 -1,665 0,004 0,156
PID_P38_MK2PATHWAY 21 -1,664 0,003 0,152
REACTOME_SIGNALLING_TO_RAS 24 -1,659 0,010 0,154
REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_ME
MBRANE
68 -1,658 0,000 0,151
PID_IL12_STAT4PATHWAY 29 -1,655 0,022 0,150
PID_IL12_2PATHWAY 54 -1,653 0,009 0,150
BIOCARTA_TOB1_PATHWAY 18 -1,648 0,016 0,152
PID_RETINOIC_ACID_PATHWAY 26 -1,646 0,017 0,151
The following gene sets from MSigDB data base (http://www.broadinstitute.org/gsea) were used: for 
human C2: curated gene sets (canonical pathways, Biocarta, KEGG and Reactome); for mouse: C2. 
The data are shown as positive and negative scoring gene sets listed in order of decreasing statistical 
significance (P value). The normalized enrichment score (NES), the normalized P value (NOM-P val) 
and false discovery rate (FDR) are shown.
GENE SET NAME SIZE NES NOM p-val FDR q-val
REACTOME_INNATE_IMMUNE_SYSTEM 166 -1,644 0,000 0,150
REACTOME_PACKAGING_OF_TELOMERE_ENDS 22 -1,641 0,007 0,149
KEGG_DORSO_VENTRAL_AXIS_FORMATION 21 -1,635 0,017 0,152
BIOCARTA_G1_PATHWAY 27 -1,633 0,007 0,151
BIOCARTA_IL10_PATHWAY 17 -1,628 0,028 0,153
ST_B_CELL_ANTIGEN_RECEPTOR 37 -1,624 0,008 0,154
BIOCARTA_TNFR2_PATHWAY 18 -1,613 0,023 0,162
REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY 50 -1,608 0,000 0,163
BIOCARTA_PYK2_PATHWAY 24 -1,604 0,026 0,164
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING 40 -1,604 0,012 0,162
PID_NFKAPPABATYPICALPATHWAY 16 -1,602 0,050 0,161
SA_G1_AND_S_PHASES 15 -1,601 0,031 0,159
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 59 -1,601 0,000 0,156
BIOCARTA_INTEGRIN_PATHWAY 34 -1,593 0,015 0,163
PID_ANTHRAXPATHWAY 16 -1,589 0,034 0,165
KEGG_RENAL_CELL_CARCINOMA 66 -1,579 0,005 0,173
BIOCARTA_NKCELLS_PATHWAY 18 -1,579 0,044 0,171
REACTOME_THE_ROLE_OF_NEF_IN_HIV1_REPLICATION_AND_DI
SEASE_PATHOGENESIS
24 -1,571 0,022 0,177
BIOCARTA_BCR_PATHWAY 30 -1,566 0,015 0,180
KEGG_JAK_STAT_SIGNALING_PATHWAY 127 -1,566 0,000 0,178
BIOCARTA_EPO_PATHWAY 17 -1,562 0,042 0,178
PID_PDGFRBPATHWAY 118 -1,561 0,000 0,178
BIOCARTA_CTCF_PATHWAY 22 -1,560 0,038 0,175
PID_IL2_1PATHWAY 51 -1,551 0,012 0,184
SA_B_CELL_RECEPTOR_COMPLEXES 22 -1,546 0,037 0,187
BIOCARTA_INFLAM_PATHWAY 26 -1,546 0,022 0,185
BIOCARTA_SPRY_PATHWAY 16 -1,541 0,043 0,188
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 28 -1,535 0,027 0,192
BIOCARTA_MAPK_PATHWAY 82 -1,532 0,000 0,193
REACTOME_SIGNALING_BY_RHO_GTPASES 85 -1,531 0,006 0,191
PID_GMCSF_PATHWAY 33 -1,531 0,024 0,189
REACTOME_MUSCLE_CONTRACTION 41 -1,529 0,017 0,189
SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES 61 -1,528 0,000 0,187
KEGG_PRION_DISEASES 29 -1,526 0,030 0,188
REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP
_KINASES_UPON_TLR7_8_OR_9_ACTIVATION
63 -1,524 0,010 0,188
BIOCARTA_ERYTH_PATHWAY 15 -1,523 0,029 0,186
BIOCARTA_CXCR4_PATHWAY 20 -1,523 0,017 0,184
BIOCARTA_IL1R_PATHWAY 31 -1,519 0,032 0,184
REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE 42 -1,515 0,024 0,186
PID_MAPKTRKPATHWAY 30 -1,515 0,021 0,185
BIOCARTA_IL22BP_PATHWAY 16 -1,514 0,034 0,184
PID_RAC1_REG_PATHWAY 31 -1,511 0,022 0,183
BIOCARTA_NFKB_PATHWAY 22 -1,501 0,046 0,192
BIOCARTA_KERATINOCYTE_PATHWAY 42 -1,494 0,020 0,199
REACTOME_SIGNALLING_TO_ERKS 32 -1,492 0,040 0,198
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING 62 -1,492 0,009 0,197
BIOCARTA_TOLL_PATHWAY 32 -1,491 0,032 0,196
BIOCARTA_NGF_PATHWAY 15 -1,489 0,050 0,196
KEGG_VIRAL_MYOCARDITIS 45 -1,489 0,021 0,194
BIOCARTA_RELA_PATHWAY 16 -1,489 0,048 0,192
REACTOME_IL_2_SIGNALING 37 -1,488 0,012 0,192
KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY 74 -1,487 0,014 0,190
PID_UPA_UPAR_PATHWAY 39 -1,474 0,030 0,205
PID_AR_PATHWAY 42 -1,471 0,032 0,205
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 101 -1,470 0,000 0,203
GENE SET NAME SIZE NES NOM p-val FDR q-val
PID_IL8CXCR2_PATHWAY 27 -1,468 0,035 0,205
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 70 -1,468 0,031 0,203
REACTOME_AMYLOIDS 38 -1,464 0,030 0,206
KEGG_TYROSINE_METABOLISM 35 -1,459 0,025 0,210
REACTOME_SIGNALING_BY_ILS 94 -1,452 0,029 0,216
REACTOME_DEVELOPMENTAL_BIOLOGY 320 -1,448 0,000 0,218
BIOCARTA_ALK_PATHWAY 34 -1,445 0,041 0,216
REACTOME_G_ALPHA1213_SIGNALLING_EVENTS 69 -1,444 0,010 0,216
PID_TCR_PATHWAY 58 -1,440 0,020 0,220
PID_P38ALPHABETADOWNSTREAMPATHWAY 35 -1,440 0,015 0,218
KEGG_GLYCOSAMINOGLYCAN_DEGRADATION 20 -1,439 0,047 0,217
PID_FOXM1PATHWAY 37 -1,422 0,031 0,232
REACTOME_SEMAPHORIN_INTERACTIONS 58 -1,411 0,033 0,243
KEGG_GLIOMA 56 -1,402 0,027 0,251
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 207 -1,395 0,000 0,254
KEGG_ADHERENS_JUNCTION 63 -1,395 0,037 0,253
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 185 -1,394 0,011 0,251
REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_
NADE
52 -1,394 0,026 0,249
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 95 -1,392 0,013 0,248
REACTOME_GENERIC_TRANSCRIPTION_PATHWAY 122 -1,391 0,007 0,248
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 112 -1,389 0,007 0,249
PID_BCR_5PATHWAY 62 -1,386 0,024 0,247
KEGG_CHEMOKINE_SIGNALING_PATHWAY 161 -1,382 0,000 0,251
human C2 positive report
GENE SET NAME SIZE NES NOM p-val FDR q-val
KEGG_RIBOSOME 77 2,820 0,000 0,000
REACTOME_PEPTIDE_CHAIN_ELONGATION 77 2,811 0,000 0,000
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TA
RGETING_TO_MEMBRANE
98 2,810 0,000 0,000
MIPS_RIBOSOME_CYTOPLASMIC 74 2,802 0,000 0,000
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REP
LICATION
90 2,797 0,000 0,000
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 84 2,774 0,000 0,000
REACTOME_TRANSLATION 121 2,743 0,000 0,000
MIPS_40S_RIBOSOMAL_SUBUNIT_CYTOPLASMIC 28 2,699 0,000 0,000
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SU
BSEQUENTLY_THE_43S_COMPLEX
32 2,689 0,000 0,000
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE
_EXON_JUNCTION_COMPLEX
90 2,644 0,000 0,000
REACTOME_INFLUENZA_LIFE_CYCLE 121 2,617 0,000 0,000
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNT
HESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTIO
N_BY_UNCOUPLING_PROTEINS_
71 2,609 0,000 0,000
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_T
HE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BIN
DING_TO_43S
39 2,594 0,000 0,000
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 55 2,432 0,000 0,000
MIPS_NOP56P_ASSOCIATED_PRE_RRNA_COMPLEX 92 2,396 0,000 0,000
MIPS_60S_RIBOSOMAL_SUBUNIT_CYTOPLASMIC 45 2,356 0,000 0,000
REACTOME_METABOLISM_OF_MRNA 181 2,337 0,000 0,000
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRAN
SPORT
100 2,311 0,000 0,000
KEGG_OXIDATIVE_PHOSPHORYLATION 101 2,265 0,000 0,000
KEGG_PARKINSONS_DISEASE 99 2,245 0,000 0,000
REACTOME_METABOLISM_OF_PROTEINS 322 2,217 0,000 0,000
GENE SET NAME SIZE NES NOM p-val FDR q-val
REACTOME_METABOLISM_OF_RNA 217 2,195 0,000 0,000
KEGG_HUNTINGTONS_DISEASE 147 1,938 0,000 0,003
KEGG_ALZHEIMERS_DISEASE 139 1,828 0,000 0,014
REACTOME_RNA_POL_II_TRANSCRIPTION_PRE_INITIATION_AND
_PROMOTER_OPENING
36 1,811 0,000 0,017
MIPS_55S_RIBOSOME_MITOCHONDRIAL 76 1,800 0,000 0,020
MIPS_TRBP_CONTAINING_COMPLEX_1 22 1,799 0,000 0,019
MIPS_26S_PROTEASOME 22 1,782 0,003 0,024
MIPS_39S_RIBOSOMAL_SUBUNIT_MITOCHONDRIAL 46 1,763 0,001 0,029
BIOCARTA_PROTEASOME_PATHWAY 26 1,758 0,007 0,030
KEGG_PROTEIN_EXPORT 19 1,753 0,004 0,031
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 111 1,731 0,000 0,040
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEAS
OME_DEGRADATION
161 1,720 0,000 0,044
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 41 1,717 0,001 0,044
KEGG_RNA_DEGRADATION 45 1,688 0,004 0,061
REACTOME_RNA_POL_II_TRANSCRIPTION 80 1,680 0,001 0,064
REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_O
DC
45 1,662 0,003 0,076
REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G 45 1,659 0,005 0,076
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_
PRESENTATION
186 1,659 0,000 0,074
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT 41 1,655 0,008 0,075
REACTOME_RNA_POL_III_TRANSCRIPTION 29 1,623 0,018 0,101
REACTOME_REGULATORY_RNA_PATHWAYS 23 1,613 0,022 0,110
REACTOME_ACTIVATED_AMPK_STIMULATES_FATTY_ACID_OXIDA
TION_IN_MUSCLE
16 1,601 0,021 0,121
MIPS_PA28_20S_PROTEASOME 16 1,601 0,018 0,119
REACTOME_BRANCHED_CHAIN_AMINO_ACID_CATABOLISM 16 1,593 0,022 0,125
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 36 1,591 0,016 0,125
REACTOME_MRNA_SPLICING_MINOR_PATHWAY 29 1,589 0,017 0,124
REACTOME_MICRORNA_MIRNA_BIOGENESIS 20 1,582 0,019 0,131
MIPS_PA700_20S_PA28_COMPLEX 34 1,578 0,012 0,134
REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TY
PE_3_PROMOTER
23 1,570 0,015 0,142
KEGG_PROTEASOME 40 1,566 0,017 0,144
REACTOME_RNA_POL_III_TRANSCRIPTION_TERMINATION 17 1,566 0,026 0,142
MIPS_RNA_POLYMERASE_II 16 1,558 0,031 0,149
KEGG_RETINOL_METABOLISM 24 1,555 0,032 0,151
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOU
S_ANTIGENS_ENDOSOMES
43 1,554 0,010 0,150
MIPS_RNA_POLYMERASE_II_HOLOENZYME_COMPLEX 23 1,547 0,027 0,157
REACTOME_RNA_POL_II_PRE_TRANSCRIPTION_EVENTS 52 1,543 0,011 0,159
KEGG_PROPANOATE_METABOLISM 27 1,542 0,022 0,158
REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 45 1,533 0,013 0,168
MIPS_LARGE_DROSHA_COMPLEX 15 1,530 0,026 0,169
REACTOME_MRNA_SPLICING 65 1,527 0,021 0,171
REACTOME_RNA_POL_III_CHAIN_ELONGATION 15 1,524 0,043 0,172
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS 32 1,520 0,034 0,176
BIOCARTA_IGF1MTOR_PATHWAY 17 1,515 0,036 0,180
KEGG_RNA_POLYMERASE 24 1,513 0,036 0,181
BIOCARTA_CK1_PATHWAY 16 1,512 0,033 0,179
REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TY
PE_2_PROMOTER
20 1,509 0,039 0,181
REACTOME_ER_PHAGOSOME_PATHWAY 49 1,506 0,024 0,184
REACTOME_ENOS_ACTIVATION_AND_REGULATION 17 1,504 0,030 0,183
PID_FOXOPATHWAY 43 1,488 0,029 0,207
KEGG_PYRIMIDINE_METABOLISM 85 1,487 0,015 0,205
GENE SET NAME SIZE NES NOM p-val FDR q-val
MIPS_17S_U2_SNRNP 27 1,484 0,039 0,208
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_E
MI1
45 1,478 0,031 0,215
REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION 61 1,478 0,029 0,213
KEGG_CARDIAC_MUSCLE_CONTRACTION 65 1,477 0,021 0,212
REACTOME_TRAFFICKING_OF_AMPA_RECEPTORS 19 1,462 0,047 0,231
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN
_COMPLEX
44 1,460 0,026 0,232
REACTOME_MRNA_CAPPING 26 1,460 0,027 0,230
REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C 53 1,458 0,031 0,230
REACTOME_APOPTOTIC_EXECUTION_PHASE 45 1,451 0,029 0,237
PID_P53REGULATIONPATHWAY 50 1,441 0,038 0,249
mouse C2 negative report
GENE SET NAME SIZE NES NOM p-val FDR q-val
GALINDO_IMMUNE_RESPONSE_TO_ENTEROTOXIN 71 -2,362 0,000 0,003
QI_PLASMACYTOMA_UP 241 -2,095 0,000 0,012
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATI
ON
101 -2,011 0,000 0,021
SHIN_B_CELL_LYMPHOMA_CLUSTER_8 35 -1,957 0,000 0,029
BROWN_MYELOID_CELL_DEVELOPMENT_UP 121 -1,949 0,000 0,026
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP 84 -1,909 0,000 0,034
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP 107 -1,883 0,000 0,038
MARKEY_RB1_ACUTE_LOF_UP 168 -1,876 0,000 0,035
LI_INDUCED_T_TO_NATURAL_KILLER_UP 213 -1,838 0,000 0,044
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP 37 -1,825 0,004 0,044
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN 64 -1,735 0,000 0,082
NADLER_OBESITY_UP 54 -1,715 0,004 0,089
NEMETH_INFLAMMATORY_RESPONSE_LPS_UP 72 -1,682 0,005 0,104
STEARMAN_TUMOR_FIELD_EFFECT_UP 28 -1,665 0,010 0,110
VILIMAS_NOTCH1_TARGETS_UP 49 -1,654 0,004 0,112
KHETCHOUMIAN_TRIM24_TARGETS_UP 44 -1,638 0,000 0,117
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN 46 -1,627 0,005 0,119
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_UP 19 -1,626 0,021 0,113
VILIMAS_NOTCH1_TARGETS_DN 18 -1,612 0,024 0,118
FUKUSHIMA_TNFSF11_TARGETS 15 -1,587 0,025 0,132
SEKI_INFLAMMATORY_RESPONSE_LPS_UP 65 -1,565 0,000 0,149
MORI_IMMATURE_B_LYMPHOCYTE_UP 41 -1,557 0,020 0,150
QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2 28 -1,540 0,043 0,162
WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP 29 -1,532 0,035 0,164
SHIN_B_CELL_LYMPHOMA_CLUSTER_3 26 -1,530 0,037 0,159
SHIN_B_CELL_LYMPHOMA_CLUSTER_5 16 -1,523 0,045 0,155
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP 144 -1,523 0,000 0,150
LIAN_LIPA_TARGETS_3M 52 -1,518 0,018 0,151
LEE_AGING_CEREBELLUM_UP 74 -1,518 0,006 0,146
ZHANG_TLX_TARGETS_36HR_UP 171 -1,496 0,000 0,163
JIANG_AGING_HYPOTHALAMUS_DN 38 -1,487 0,020 0,170
BILANGES_SERUM_SENSITIVE_GENES 69 -1,439 0,000 0,225
LIAN_LIPA_TARGETS_6M 65 -1,437 0,032 0,222
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_U
P
52 -1,423 0,034 0,234
KASLER_HDAC7_TARGETS_1_UP 142 -1,415 0,000 0,241
mouse C2 positive report
GENE SET NAME SIZE NES NOM p-val FDR q-val
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES 59 2,515 0,000 0,000
MODY_HIPPOCAMPUS_PRENATAL 36 2,182 0,000 0,000
MILI_PSEUDOPODIA_HAPTOTAXIS_UP 332 2,146 0,000 0,000
SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP 125 2,043 0,000 0,002
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13 126 1,960 0,000 0,005
WANG_LSD1_TARGETS_UP 20 1,950 0,000 0,005
ZHANG_BREAST_CANCER_PROGENITORS_UP 281 1,892 0,000 0,015
LANDIS_ERBB2_BREAST_TUMORS_324_DN 125 1,890 0,000 0,013
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_D
N
23 1,876 0,000 0,015
BURTON_ADIPOGENESIS_11 42 1,827 0,000 0,024
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_UP 86 1,823 0,000 0,023
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10 43 1,813 0,000 0,024
BURTON_ADIPOGENESIS_5 90 1,770 0,000 0,040
WANG_TUMOR_INVASIVENESS_UP 288 1,751 0,000 0,049
BURTON_ADIPOGENESIS_12 21 1,749 0,004 0,047
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN 48 1,732 0,000 0,055
LANDIS_BREAST_CANCER_PROGRESSION_DN 62 1,732 0,001 0,052
STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN 338 1,726 0,000 0,053
JIANG_AGING_HYPOTHALAMUS_UP 39 1,723 0,000 0,052
MILI_PSEUDOPODIA_CHEMOTAXIS_UP 39 1,710 0,001 0,057
LANDIS_ERBB2_BREAST_TUMORS_65_DN 30 1,704 0,004 0,059
GOLDRATH_HOMEOSTATIC_PROLIFERATION 123 1,704 0,001 0,056
PLASARI_TGFB1_TARGETS_10HR_DN 193 1,696 0,000 0,059
ZHANG_TLX_TARGETS_36HR_DN 122 1,688 0,001 0,063
ELLWOOD_MYC_TARGETS_DN 26 1,686 0,008 0,062
BOUDOUKHA_BOUND_BY_IGF2BP2 82 1,685 0,000 0,059
PLASARI_NFIC_TARGETS_BASAL_DN 17 1,685 0,010 0,058
IKEDA_MIR30_TARGETS_UP 107 1,684 0,000 0,056
MCBRYAN_PUBERTAL_BREAST_5_6WK_UP 84 1,681 0,000 0,056
CUI_TCF21_TARGETS_UP 32 1,673 0,009 0,059
BURTON_ADIPOGENESIS_6 145 1,655 0,000 0,070
JIANG_AGING_CEREBRAL_CORTEX_UP 32 1,614 0,007 0,108
ZHENG_FOXP3_TARGETS_IN_THYMUS_UP 133 1,607 0,000 0,112
CADWELL_ATG16L1_TARGETS_UP 68 1,601 0,004 0,115
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP 98 1,593 0,002 0,122
PAL_PRMT5_TARGETS_UP 160 1,591 0,001 0,121
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4 200 1,578 0,000 0,135
HOWLIN_PUBERTAL_MAMMARY_GLAND 59 1,578 0,005 0,132
PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_UP 42 1,571 0,007 0,137
BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2 52 1,559 0,010 0,151
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4
K20ME1_MARK
95 1,558 0,002 0,147
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP 209 1,555 0,001 0,148
MORI_SMALL_PRE_BII_LYMPHOCYTE_UP 68 1,553 0,011 0,147
KARLSSON_TGFB1_TARGETS_DN 156 1,548 0,001 0,150
RUAN_RESPONSE_TO_TNF_DN 74 1,545 0,009 0,151
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_TOP20_UP 17 1,520 0,043 0,188
SWEET_LUNG_CANCER_KRAS_DN 367 1,517 0,000 0,191
CUI_TCF21_TARGETS_2_UP 299 1,516 0,000 0,189
IGLESIAS_E2F_TARGETS_UP 129 1,505 0,002 0,201
HANSON_HRAS_SIGNALING_VIA_NFKB 18 1,504 0,043 0,199
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN 175 1,504 0,003 0,196
GENE SET NAME SIZE NES NOM p-val FDR q-val
PILON_KLF1_TARGETS_UP 365 1,499 0,000 0,202
MARTINEZ_TP53_TARGETS_UP 459 1,498 0,000 0,198
CHESLER_BRAIN_HIGHEST_EXPRESSION 30 1,493 0,044 0,205
NADLER_OBESITY_DN 44 1,493 0,029 0,201
BILANGES_SERUM_RESPONSE_TRANSLATION 30 1,491 0,029 0,202
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN 395 1,488 0,000 0,203
LANDIS_ERBB2_BREAST_TUMORS_65_UP 18 1,484 0,049 0,206
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_DN 27 1,483 0,049 0,204
YU_MYC_TARGETS_UP 34 1,479 0,031 0,209
MARKEY_RB1_ACUTE_LOF_DN 178 1,477 0,001 0,209
WANG_TARGETS_OF_MLL_CBP_FUSION_DN 34 1,477 0,043 0,206
WANG_CLASSIC_ADIPOGENIC_TARGETS_OF_PPARG 24 1,477 0,039 0,203
MARTINEZ_RB1_AND_TP53_TARGETS_UP 465 1,455 0,001 0,230
RAMALHO_STEMNESS_UP 157 1,455 0,008 0,227
IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM 18 1,453 0,048 0,228
